Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 14, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for the second quarter of 2025 and provided a business update.</li><li>The company recently presented positive results from the Phase 1 clinical trial of CDI-988 at the 2025 Military Health System Research Symposium.</li><li>The data showed that all doses of CDI-988, from 100 mg to 1200 mg, were well tolerated.</li></ul>

On August 14, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for the second quarter of 2025 and provided a business update.The company recently presented positive results from the Phase 1 clinical trial of CDI-988 at the 2025 Military Health System Research Symposium.The data showed that all doses of CDI-988, from 100 mg to 1200 mg, were well tolerated.

COCP: Norovirus Challenge Study to Initiate in 4Q25 